Compare Kroger Co (KR) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs Natera Inc. Common Stock — how do they compare? Kroger Co trades at $63.88 (market cap $35.87B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Kroger Co pays a 2.57% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kroger Co for 109 Days and Natera Inc. Common Stock for 0 Days on average.
| KR | NTRA | |
|---|---|---|
Market Cap | $35.87B | $57.03B |
Volume | 8,902,665 | 1,131,157 |
Sector | Consumer Staples | Health |
52-Week High | $75.60 | $425.64 |
52-Week Low | $55.53 | $179.42 |
Typical Hold Time | 109 Days | 0 Days |
Enterprise Value | $57.29B | $56.18B |
Dividend Yield | 2.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $60.74, down 2.91% on the day, with a bullish technical signal and a consensus analyst price target of $70.62. The stock shows strong cash flow generation ($2.08B net in 2025) and a low P/S ratio of 0.26, but faces margin pressure with a net income margin of 0.73%. Recent news highlights digital growth initiatives and a focus on everyday low prices under new leadership.
The outlook is balanced: upside exists from valuation support and e-commerce expansion, but risks include integration challenges from acquisitions and softer sales guidance. Analysts are moderately bullish, yet near-term performance hinges on execution against cost pressures and competitive dynamics in the grocery sector.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
